-
Mashup Score: 0Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Peripheral T-cell Lymphoma - 1 year(s) ago
/PRNewswire/ — Secura Bio, Inc. (Secura Bio) – (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and…
Source: www.prnewswire.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and…
Source: Journal of Clinical OncologyCategories: Hematologists1, Latest HeadlinesTweet-
RT @smbenlazar: Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma https://t.co/QzGrwz8v80 #DLBCL #lysm https://t…
-
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Glofitamab for r/r DLBCL N=154 Med fu of 12.6mo CR 39% in total population CR 35% (prior CART) Median time to a CR 42 days 78% ongoing CR at 12mo Gr >=3CRS 4% Gr >=3 neurotox 3% #ASHkudos to @mike_dickinson1 #ASH22 #lysm https://t.co/2iN83AXW6n
-
-
Mashup Score: 0FDA Takes Tougher Line on Fast-Tracked Drugs - 1 year(s) ago
GSK and Roche have pulled drugs approved on an accelerated basis, while other drugmakers win speedy approvals only after starting confirmatory studies.
Source: WSJCategories: Hem/Oncs, Latest HeadlinesTweet-
Success is never guaranteed in life but preparing to minimize unwanted effects of failure 😞 is imp. Impressed with #FDA plans on making sure #Acceleratedapproval gets the drugs out to pt, with checks and balance. #patientcare #mmsm #lysm https://t.co/QNl1WkjuLh
-
-
Mashup Score: 0FDA Grants Priority Review to Subcutaneous Epcoritamab for Previously Treated R/R LBCL - 1 year(s) ago
Based on positive findings from the phase 2 pivotal EPCORE NHL-1, the FDA will conduct a speedy review of the biologics license application for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has accepted the BLA for subcutaneous epcoritamab for the treatment of patients with relapsed/refractory large B-cell lymphoma after 2 or more lines of systemic therapy an granted it priority review. #lbcl #lysm https://t.co/HWs6acySO4
-
-
Mashup Score: 2Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy - 1 year(s) ago
Key Points. Patients without detectable lymphoma at the time of CD19 CAR T-cell therapy had excellent outcomes.Administering CD19 CAR T-cell to patients without
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Our #CARTcells consortium study led by @Kwudhikarn now out in @BloodAdvances Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy #lysm https://t.co/aB45p2smJq
-
-
Mashup Score: 0How Are Lab Test Reference Ranges Determined? - 2 year(s) ago
What do lab test reference ranges mean, and how are they established? Drs.
Source: Patient PowerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What do lab tests reference ranges mean, and how are they established? Experts Dr. Susan Leclair and Dr. William Wierda delve into a deeper understanding of what your lab results mean and how they are interpreted: https://t.co/APvMM1EotU #leusm #mmsm #bcsm #lcsm #mpnsm #lysm
-
-
Mashup Score: 0Non-Hodgkin Lymphoma - 2 year(s) ago
Non-Hodgkin lymphoma (NHL) is a blood cancer that develops in the lymphatic system. It usually starts in the lymphocytes, which are a type of white blood cell, and because lymphocytes are all over the body, it can grow in other parts of the body as it travels through the blood and lymphatic system.
The World Health Organization has identified more than 60 different subtypes of NHL.
Source: Patient PowerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What is the highest risk factor for #NHL? How does Non-Hodgkin Lymphoma develop? In light of #JaneFonda's diagnosis, here's some need-to-know info surrounding the disease: https://t.co/QFGCdIX5Ab #lysm https://t.co/ed3idVlY5C
-
-
Mashup Score: 0tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma - 2 year(s) ago
Key Points. A new TMTV/ECOG-PS prognostic score was validated in 2174 DLBCL patients of all ages treated in clinical trials and real-world series.The combined T
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
TMTV & ECOG-PS as a prognostic score for newly diagnosed DLBCL Patients with intermediate (1 risk factor) or high (2 risk factors) had significantly worse outcomes than patients with no risk factors #lysm https://t.co/bkAxQuvFPM
-
-
Mashup Score: 1What the Inflation Reduction Act Means for People With Cancer - 2 year(s) ago
Congress passed the Inflation Reduction Act which has implications for people with cancer. Learn more.
Source: Patient PowerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn How the #InflationReduction Act Impacts People With Cancer While the bill covers a lot in its 730 pages, there are 3 main takeaways for people with cancer. The Inflation Reduction Act: https://t.co/PuAJuj5SQc #leusm #lcsm #bcsm #mmsm #mpnsm #lysm #oncotwitter https://t.co/ai6A45pmpB
-
🚨 NEWS 🚨 @EU_Commission grants orphan drug designation to duvelisib for the treatment of peripheral T-cell lymphoma. https://t.co/5YHCUPwtdP #mednews #lysm https://t.co/ezDSBRDV1O